Back to Search
Start Over
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.
- Source :
-
Endocrine-related cancer [Endocr Relat Cancer] 2016 Aug; Vol. 23 (8), pp. R337-52. Date of Electronic Publication: 2016 Jul 12. - Publication Year :
- 2016
-
Abstract
- The majority of breast cancers may be considered hormone responsive due to expression of hormone receptors (HR+). Although endocrine therapy is always considered for advanced HR+ breast cancer, the emergence of resistance is inevitable over time and is present from the start in a proportion of patients. In this review, we explore the mechanisms underlying de novo and acquired resistance to endocrine therapy. We comprehensively review newly approved and emerging therapies that have been developed to counteract specific mechanisms of resistance. We discuss the challenges pertinent to this therapeutic arena including the potential relief of negative regulatory feedback inhibition with compensatory pathway activation and the evolution of molecular changes in HR+ breast cancers during treatment. We discuss strategies to address these challenges in order to develop rational therapy approaches for patients with advanced HR+ breast cancer.<br /> (© 2016 Society for Endocrinology.)
- Subjects :
- Autophagy
Breast Neoplasms genetics
Breast Neoplasms metabolism
Cell Cycle
Estrogen Receptor alpha genetics
Female
Humans
Mutation
Phosphatidylinositol 3-Kinases metabolism
Protein Kinases metabolism
Receptors, Growth Factor metabolism
Signal Transduction
Antineoplastic Agents, Hormonal therapeutic use
Breast Neoplasms drug therapy
Drug Resistance, Neoplasm genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1479-6821
- Volume :
- 23
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Endocrine-related cancer
- Publication Type :
- Academic Journal
- Accession number :
- 27406875
- Full Text :
- https://doi.org/10.1530/ERC-16-0121